Biological limits of lifespan extension: evidence for a shift from pathway leverage to system-level buffering across species
What this study shows
mTOR/TOR pathway interventions achieve large lifespan extensions in simple organisms but face declining efficacy in mammals due to distributed multi-tissue buffering, redundancy, and pharmacokinetic complexity - proposing a unifying framework for the translational challenge of aging pathway targeting.
At a glance
| Evidence type | R Review — secondary literature, not a new result Marked R because it is a review or synthesis of existing evidence rather than a new primary result; that is a different form of writing, not a weaker one. |
| Study type | Narrative Review |
| Model system | Multi-species (C. elegans, Drosophila, rodents) |
| Journal | Mechanisms of Ageing and Development |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1016/j.mad.2026.112231 · PMID 42437600 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | TOR/mTOR pathway interventions (rapamycin and analogues) |
| Target | TOR/mTOR signaling; conserved aging pathways |
| Model | Multi-species |
| Effect | Lifespan extension via mTOR inhibition declines with organismal complexity; mammals show system-level buffering that limits single-pathway leverage |
In the Atlas
Related topics
More studies on this topic
- Disruption of the insulin/IGF-1 signaling pathway in Caenorhabditis elegans dramatically increases male longevity and enhances reproductive health late in life (2026)
- Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice (2011)
- Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice (2016)
- Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls (2014)
Was this page useful?
Thank you. Your answer was counted anonymously.